Fidaxomicin: 5 agencies, 2012–2024
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
On the same population the two systems disagree outright: SMC (Scotland) recorded restricted for “Treatment of clostridim difficile infections (CDI) also known as C. Difficile-associated diarrhoea (CDAD)”, while AWMSG (Wales) recorded not recommended for “Treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in paediat…”.
Where fidaxomicin met resistance it was usually narrowed rather than refused: 4 of 10 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
Assessment has run over 11.6 years, from 9 Jul 2012 at SMC (Scotland) to 14 Feb 2024 at HAS (France).
AWMSG (Wales) changed its position: restricted on 13 Dec 2012, not recommended by 24 Jun 2021.
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
3 distinct indication wordings are recorded for fidaxomicin by the agencies that label one in English (AWMSG and SMC).
SMC (Scotland) was first to assess fidaxomicin, on 9 Jul 2012; TLV (Sweden) did not open a file until 5 Jun 2014 — a moderate spread of 1.9 years between the earliest and latest system to look at it.
Restriction is doing real work here: 4 of 10 decisive outcomes narrowed fidaxomicin to a subgroup rather than accepting or refusing it outright, at AWMSG (Wales), SMC (Scotland) and TLV (Sweden).
4 of the 5 agencies here assessed fidaxomicin more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed fidaxomicin.
The full ledger for fidaxomicin reads 5 recommended, 4 restricted and 1 not recommended.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 14 Feb 2024 | Change to listing conditions (Transparency Committee) | SMR substantial · ASMR III | source |
| TLV (Sweden) | 1 Dec 2022 | Dificlir, granulat till oral suspension, ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| AWMSG (Wales) | 24 Jun 2021 | Treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in paediat… | not endorsed (non-submission) | source |
| G-BA (Germany) | 3 Sep 2020 | Dificlir — benefit assessment §35a | added benefit: considerable (hint) | source |
| SMC (Scotland) | 9 Jul 2012 | Treatment of clostridim difficile infections (CDI) also known as C. Difficile-associated diarrhoea (CDAD) | accepted (restricted) | source |
5 further decisions for fidaxomicin, across 4 agencies, are not shown here. They link to 3 further source documents.
Related molecules
- rifaximin — same ATC class A07A — Antidiarrheals / intestinal anti-inflammatories
- vancomycin — same ATC class A07A — Antidiarrheals / intestinal anti-inflammatories
- futibatinib — also decided by HAS in 2024Q1
- empagliflozin — also decided by HAS in 2024Q1
- enoxaparin — also decided by HAS in 2024Q1
- burosumab — also decided by HAS in 2024Q1
Coverage: 10 decisions for fidaxomicin from 5 agencies, 2012 to 2024. Data to 7 Sep 2026. ATC class A07A — Antidiarrheals / intestinal anti-inflammatories. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.